anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
PROBLEM TO BE SOLVED: To obtain a composition in which an azulene derivative is stabilized in high level even in an aqueous solution. SOLUTION: Stability of the azulene derivative to lights is improved by adding 0.01-100000 pts.wt. xanthine (caffeine, theophylline or the like) to 1 pt.wt. azulene derivative such as sodium guaiazulene sulfonate. The composition of this invention is allowed to contain 0.01-1000 pts.wt. chelating agent (e.g. edetic acid or the like). The composition of this invention is useful as a water-based composition, e.g. the composition for topical application such as an ophthalmic solution or the like and the composition for application to mucosa.
The invention discloses a medicament for treating gout. The medicament is a Tibetan medicine and is also called Shisiwei Tongfengding, which is composed of an active component or is composed of active ingredients and pharmaceutically acceptable accessories. The active component is prepared from Tinospora sinensis Merr, (pitted) Terminalia chebula Retz., Acorus calamus L., Semen Cassiae, Corydalis impatiens (Pall.) Fisch, (pitted) Fructus Terminaliae Billericae, frankincense (processed), ambrette, benzoin, acaciae catechu, Yanjinggao, (pitted) Phyllanthus emblica L., radix aucklandiae, and copper ash (processed) in certain weight proportion. The medicament can be prepared into any forms of common preparations for oral administration. With the functions of dispelling wind, eliminating dampness, diminishing inflammation, relieving pain and removing yellow water, the medicament provided in the invention can be used for treating arthritis, rheumatoid arthritis, gout, arthrocele, pain and deformation of limbs as a result of arthralgia diseases, stiff limbs, and yellow water accumulation, etc.
Spheroid microtissues can mimic native tissue-like structure and function, and are thus useful for broad research applications and regenerative medicine. Disclosed embodiments include spheroid production methods that are high-throughput, suitable for efficient production, maintainable over long-term culture, and/or offer repeatable control over size distribution. Embodiments disclosed include spheroids that include blood vessels, which are proven useful for tissue survival and function. Embodiments include spheroids with functional, blood-perfused vascular networks upon injection in vivo. Dissolvable hydrogel microwell arrays enable high throughput parallel formation of spheroids in a single pipetting step and easy retrieval for downstream applications. Dynamic culture conditions stimulated endothelial cell and mesenchymal stem cell cocultures to self-organize and form blood-vessel structures within the spheroids. Vascularized spheroids were injected into mice and rapid perfusion of implant vessels within 4-7 days were observed.
This study is a longitudinal study that adopts a double-blind randomized controlled trial (RCT). The study will recruit 120 male nurses and allocate them into the intervention group and the control group in a 1:1 ratio (60 in each group). Based on Super's (1957) career development theory and the four-stage career classification, the participating male nurses will be divided into the exploration stage (experience ≤ 2 years), establishment stage (experience 2-5 years), and maintenance stage (experience 5-15 years), with career stage as a confounding factor. The study uses 1:1:1 stratified randomization to ensure that the number of cases in the experimental group (n=60, exploration stage: establishment stage: maintenance stage = 20:20:20) and the control group (n=60) is the same, as well as the homogeneity of the career stage variables of the two groups. All included subjects will undergo an online pre-test (T0) before allocation, and then enter the experimental group or the control group according to the random assignment results. Both groups will be invited to use the "Building Your Successful Nursing Career" App for six months, with the experimental group receiving the full career planning mobile application intervention and two online Career Mentoring Programs, while the control group receives a sham treatment. Both groups will undergo five follow-up online data collections (0, 6, 12, 18, and 24 month post-intervention). The effectiveness of the career planning mobile application intervention on male nurses' career self-efficacy, career adaptive behaviors, occupational resilience, career success, and career continuity intentions will be examined using the intention-to-treat analysis method and General Estimating Equations (GEE).
Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine \[45 μg\], Cohort 2: middle dosage of RSV F subunit vaccine \[90 μg\], and Cohort 3: high dosage of RSV F subunit vaccine \[135 μg\]). This placebo group belongs to Cohort 3.
The coarctation of the aorta (CoA) combined with heart defects or cerebral artery aneurysms is more prevalent in clinical practice. However, cases of concurrent bilateral iliac artery dissection (IAD) are extremely rare and have not been reported. Here, we described a case with CoA combined with bilateral IAD. The patient, a 62-year-old male, presented with acute intermittent claudication accompanied by pain and aching in both lower limbs after walking. Following a thorough medical history inquiry and examination, the patient was diagnosed with acute bilateral IAD combined with CoA. The patient underwent endovascular treatment. Postoperatively, the aortic diameter recovered, and the bilateral IAD disappeared, yielding satisfactory therapeutic results. Conclusively, endovascular treatment of aortic coarctation combined with IAD is an effective therapeutic approach, enhancing patient survival and improving their quality of life.
A system, method, and computer-readable media are provided for facilitating clinical decision making, and in particular, decision making based on a third party's clinical situation by determining and providing useful, up-to-date information, such as patient-related information to a decision maker. In one embodiment, a user first identifies an information item concerning a patient. Based on that item, a set of related information items is determined and prioritized, and a reference pointer, which identifies the set of related information, is generated. The reference pointer is communicated to the user's mobile device. Subsequently, the user's mobile device requests information from the set of information items associated with the reference pointer, and provides information authorization information. Following authentication of the user's credentials, updates of information from the set of information items may be communicated to the user's mobile device as they become available.
INDOCIN has been shown to be an effective anti-inflammatory agent, appropriate for long-term use in rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis.

INDOCIN affords relief of symptoms; it does not alter the progressive course of the underlying disease.

INDOCIN suppresses inflammation in rheumatoid arthritis as demonstrated by relief of pain, and reduction of fever, swelling and tenderness. Improvement in patients treated with INDOCIN for rheumatoid arthritis has been demonstrated by a reduction in joint swelling, average number of joints involved, and morning stiffness; by increased mobility as demonstrated by a decrease in walking time; and by improved functional capability as demonstrated by an increase in grip strength. INDOCIN may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis. In such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects.
Cotton pad was applied as protective filling material. Standard 250 mmHg pressure was applied as pneumatic tourniquet pressure.
This is a parallel-controlled study. A total of 2,750 participants will be enrolled in this study: 9-14 years (2 doses) group and 9-19 years (3 doses) group are of non-randomized, open label design; 20-26 years (3 doses) group will be randomized and blinded.

9-14 age group and group 9-19 age group will be enrolled in two stages: 20 subjects in 9-19 age group will be enrolled first. After assessing the safety data (including laboratory test data) within 7 days of 1st dose vaccination in these 20 subjects, and if the suspension criteria are not met, the remaining 620 subjects in 9-19 age group and 640 subjects in 9-14 age group will be enrolled subsequently. 20-26 age group will be enrolled directly, with no stage entry requirements. Eligible subjects will be enrolled to received vaccines accordingly. Subjects who have reached menarche will undergo urine pregnancy test prior to each dose of vaccination (on the vaccine day.)
PROBLEM TO BE SOLVED: To obtain the subject inhibitor capable of controlling ectopic calculation, having high safety by making the inhibitor include hyaluronic acid (salt) as an active ingredient. SOLUTION: This inhibitor contains hyaluronic acid (salt) as an active ingredient. The weight-average molecular weight of hyaluronic acid is preferably 3,000-4,000,000, more preferably 10,000 to 2,000,000. When hyaluronic acid is used as a medicine, it is preferably in the form of a salt. An alkaline (earth) metal salt, a quaternary ammonium salt, etc., may be cited as the salt, an alkali metal salt is preferable and sodium salt is more preferable. Wound such as sprain, burn, etc., or calcification by inflammation, dermatomyositis, scleroderma, calcific tendinitis, calcific synovial capsulitis, cartilaginous calcinosis, localized calcinosis, etc., may be cited as the diseases to which the inhibitor is applied. The dose of hyaluronic acid is preferably about 100 μg/kg to 10 mg/kg daily.
Between 1990- and 2003, we identified in Ontario, and subsequently across Canada, a striking increase in hospital admissions for asthma in children occurring predictably in the third week of September every year.1 In 2000 we undertook a retrospective case-control study comparing the clinical characteristics of children using local emergency rooms for asthma in September, with those of children presenting during the non-epidemic months of July-August. Based on that pilot study of 169 children, we developed a larger prospective case-control study of clinical and biological characteristics of children recruited as they presented to an emergency room for asthma during September 2001. The control group for this study were children recruited from the community who had symptomatic asthma but did not have a September exacerbation requiring emergency room utilization. We identified the presence of rhinovirus in the majority of children attending an ER with acute asthma, and also found rhinovirus in a substantial proportion of the community based controls. We also found a highly significant difference in use of medications for asthma, with the ER cases being much less likely to be receiving adequate anti-inflammatory medication. In September 2004 we conducted a pilot randomized controlled blinded clinical trial of the efficacy of montelukast in reducing morbidity caused by asthma exacerbations associated with respiratory viral infections (RVI) in children aged 2 to 14. We found a highly significant reduction in reported symptom free days in the montelukast group. The current study is a randomized placebo-controlled trial of montelukast, during September 2005 to confirm the results of our pilot study and to examine the effectiveness of montelukast in reducing asthma morbidity during RVIs in different age and sex groups with a range of risk of exacerbations. We also wish to compare the effectiveness of montelukast to placebo in reducing asthma morbidity during RVIs between groups of children concurrently taking no or other classes of asthma control medications.
The gold standard treatment for specific phobias is exposure therapy, wherein the individual repeatedly faces the object of their fear. However, for many patients, the level of distress prohibits them from either starting or completing exposure therapy. The objective of this application is to use focal neuro-reinforcement based on decoded fMRI information (from the ventral temporal temporal cortex) to reduce fear responses to feared animal stimuli (e.g., spiders, birds) in individuals with phobias, directly and unconsciously in the brain, without repeatedly consciously exposing participants to their feared stimuli. Because the induced representations are unconscious, participants do not experience negative emotional responses and the procedure is double-blind placebo-controlled, thus providing a level of experimental rigor not afforded to standard psychological therapies. Extending from our pilot data, we are positioned to test the mechanisms and behavioral outcomes of a novel treatment for phobias that at the same time advances our understanding of the role of consciousness in fear responses and their change over time. The specific aims are to: (1) confirm that our method engages the neurobiological target (amygdala reactivity to images of feared animals) in a population of individuals with specific phobias of animals; (2) quantify how changes in amygdala reactivity with neuro-reinforcement mediate changes in behavioral outcomes, as measured by attentional capture, approach/avoidance behavior, or subjective fear ratings, immediately post neuro-reinforcement; (3) assess the longer term effects four weeks after neuro-reinforcement; and (4) explore the impact of three dosage levels of neuro-reinforcement to identify the optimal dosage for future research. If proven effective, the results will inform applications for other fear related disorders, such as posttraumatic stress disorder, social anxiety disorder and panic disorder.
Attention-Deficit Hyperactivity Disorder (ADHD) affects 2.8% of adults and 5.9% of youth worldwide, and is more prevalent in males compared to females. There are both genetic and environmental risks for developing ADHD. As such, the condition is an epigenetic disorder with a complex pathophysiology that includes numerous biological pathways. Numerous co-morbidities are associated with ADHD including obesity, asthma, diabetes mellitus, and somatic disorders. Individuals diagnosed with ADHD are more likely to attempt and complete a suicide attempt. Chronic illnesses associated with ADHD are shown to develop early in life and track into adulthood. Thus, ADHD is a significant public health issue. The Healing Minds intervention will be implemented by a trained and certified pediatrician, health care or research staff member to children and adolescents diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD). The proposed study will determine if the intervention is safe and effective compared to a placebo condition. The Healing Minds intervention includes a biofeedback component and breathing practices. Biofeedback is a type of mind-body technique used to control body functions such as heart, lung and muscle responses. Biofeedback uses therapeutic techniques that aim to help study participants gain more awareness and control over certain physiological functions in their bodies. It involves the use of electronic monitoring equipment to provide real-time information about physiological processes such as heart rate, heart rate variability and muscle tension. This information is then provided back to the study participant, allowing participants to learn how to consciously regulate these processes. During the sessions parents are expected to attend and participate. Study participants and parents will have access to a video that provides instructions for placement of the Heart Math single small ear lobe or finger sensor. Breathing Practices include alternate nostril, qi gong and other breathing practices. Biofeedback and breathing practices will be employed to help the study participants to: 1) Improve attention and focus by training the participants to regulate brainwave patterns and improve concentration, 2) Develop emotional regulation skills, helping study participants become more resilient in the face of stressors, 3) Control physiological responses can contribute to overall emotional well-being.
<P>PROBLEM TO BE SOLVED: To provide use of esterquat as sand repellent in a composition.  <P>SOLUTION: The esterquat generating sand-repelling action in the composition is used in the composition containing a cosmetic composition. The cosmetic composition is used e.g. for protecting the skin from ultraviolet light by topically applying the cosmetic composition having the sand-repelling action to the skin. The esterquat, being at least one kind of esterquat containing an alkanol amine imparting sand repelling action to the composition as a base, in which the acyl component is derived from (a) monocarboxylic acid, (b) dicarboxylic acid, (c) tricarboxylic acid or a mixture thereof is used in the composition.  <P>COPYRIGHT: (C)2008,JPO&INPIT
This study will be a Phase I, randomized, placebo-controlled study in healthy subjects and asthma patients, performed at 2 study centers. The study will consist of 3 parts (Part 1 \[SAD in healthy subjects\]; Part 2 \[SAD in asthma patients\]; Part 3 \[MAD in healthy subjects under fasted conditions, with one cohort participating under fed conditions during one day as well\]). The SAD cohorts in Parts 1 and 2 of the study will include male and women of non-childbearing potential (WONCBP) until the exposure limit for males has been reached. If an additional cohort for Parts 1 and 2 with a dose exceeding exposure limits in males is warranted (to explore the upper end of the dose response curve), this will be conducted in WONCBP only. Cohorts in Part 3 will include male subjects and WONCBP, depending on recruitment feasibility. All cohorts in the study will be single-blinded.
Subjects will receive Treatment A in Period 1, Treatment B in Period 2 and then Treatment C in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
These subjects will be treated with identically appearing placebo i.v. on the same schedule as the experimental arm subjects (i.e., three "loading" doses, two weeks apart, followed by five more monthly infusions. Again, the final assessment will be performed at month 7 (210+10 days after treatment start).
The invention relates to substances regulating alpha-synuclein accumulation and their pharmaceutical application. The invention discloses a class of compounds for the first time. The compounds can interact with alpha-synuclein (alpha-Syn), and can promote the formation of alpha-Syn protein disomes, thus speeding up accumulation of the alpha-Syn and formation of fiber. In general, alpha-Syn oligomers have the greatest toxicity on cells. The compounds can promote accumulation of the alpha-Syn to form fiber or lumps, thereby reducing toxicity of the alpha-Syn on cells. Furthermore, the invention also for the first time reveals that the 118-130th amino acid sequence region at the C- end of the alpha-synuclein is the interaction site of the alpha-Syn and the compounds, and can serve as a potential drug target.
Infections of upper respiratory tract are common in the population, and its treatment, in most cases involves the use of symptomatic drugs. Paracetamol is used as an analgesic and antipyretic, while chlorpheniramine is an antihistamine and a vasoconstrictor phenylephrine decongestant function. This study aimed to evaluate the efficacy and safety of the oral solution of paracetamol, chlorpheniramine maleate and phenylephrine hydrochloride in reducing symptoms of flu and the common cold. There will be a randomized, double-blind, placebo-controlled trial. Volunteers will be recruited through posters down at the Hospital de Clinicals de Porto Alegre, and care in the public hospital network, which will undergo a screening questionnaire on first contact. With a statistical power of 80% and the possibility of random error of 5% should be followed in this study 194 subjects. Whereas a loss of up to 10% will be included 216 subjects, male or female, aged greater than 12 and less than or equal to 60 years, irrespective of color and / or race with symptoms of recent onset, for more than 6 hours and less than 48 hours, characterizing one of the following conditions: Common Cold, which consists of at least 3 symptoms among the 10 following: sneezing, rhinorrhea, nasal congestion, headache, muscle pain, throat discomfort, pain throat, dysphonia, cough, fever, and these moderate or severe using a scale of severity of symptoms of 4 points (0 = none, 1 = mild, 2 = moderate, 3 = severe) and / or Influenza consisting fever of at least 38.1 ° C and headache of moderate or severe or myalgia / arthralgia moderate or severe using a scale of severity of symptoms of 4 points (0 = none, 1 = mild, 2 = moderate , 3 = severe). Will be included only subjects who agree with the Terms of Consent. Not be included in the study pregnant women or infants with known hypersensitivity to components of the formula, or research subjects that are experiencing chronic active or exacerbated. After clinical evaluation and laboratory research subjects will be randomized to receive active drug or placebo, 10 ml oral solution every 6 hours for 48 hours. Be provided paracetamol rescue co-intervention. Study subjects will receive a diary containing questionnaires of symptoms. The follow-up visits will be held on 2 (24 hours after first intervention) and in 3 days (48 hours after first intervention). The outcomes to assess the effectiveness so far consist of scores of symptoms, rescue medication use, improvement of fever, subjective evaluation of palatability and tolerance and treatment compliance. To evaluate the safety of the drug will be accompanied by the emergence of adverse events
This was a double-blinded, randomized, placebo-controlled trial performed in an urban, academic pediatric emergency department with an annual census of 67,000 patients. Children 6-12 years old for whom IN midazolam was ordered were eligible for enrollment. Patients were randomly assigned an identical intranasal medication (4% Lidocaine or 0.9% saline). Patients were administered the study drug followed by IN midazolam. Patients then assigned a pain score for midazolam administration using the Wong-Baker FACES Pain Rating scale. The primary endpoint of pain score was analyzed with a two-tailed Mann-Whitney U test, with P \< 0.05 considered statistically significant.